Study of ZGGS18 in Patients With Advanced Solid Tumors
ConditionAdvanced Solid Tumor
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSuzhou Zelgen Biopharmaceuticals Co.,Ltd
About this trial
A clinical study to assess dose escalation, tolerance, safety, pharmacokinetics, and multi cohort expansion of ZGGS18 in patients with advanced solid tumors
Eligibility criteria
Qualifiers
Histologically or cytologically confirmed diagnosis of advanced solid tumors, who had failed the available standard treatments or no standard treatment or intolerance to standard treatment;
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;
Life expectancy ≥ 3 months;
Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors 1.1(RECIST1.1). For lesions that have received radiation therapy, only after the progression of the lesions, they can be considered measurable lesions.
Disqualifiers
The investigator considers that any subjects are not suitable to participate in the trial.
Trial design
Treatments tested in this trial
- ZGGS18 for Injection
- ZGGS18 for Injection
Treatment groups
222 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov